MeSH term
Frequency | Condition_Probility | Female | 457 | 0.0 |
Humans | 1235 | 0.0 |
Pregnancy | 56 | 0.0 |
Pregnancy Outcome | 3 | 1.0 |
Pregnancy, Multiple | 2 | 1.0 |
Randomized Controlled Trials | 3 | 0.0 |
Acute Disease | 13 | 0.0 |
Adult | 329 | 0.0 |
Comparative Study | 137 | 0.0 |
Patient Selection | 2 | 1.0 |
Animals | 257 | 0.0 |
*CpG Islands | 5 | 6.0 |
Dendritic Cells/*immunology | 4 | 1.0 |
Flow Cytometry | 28 | 0.0 |
Lymphocyte Activation | 17 | 0.0 |
Lymphocyte Culture Test, Mixed | 12 | 1.0 |
Mice | 91 | 0.0 |
Mice, Inbred C57BL | 21 | 0.0 |
Research Support, Non-U.S. Gov't | 701 | 0.0 |
Time Factors | 36 | 0.0 |
Factor V/*physiology | 3 | 75.0 |
Point Mutation/physiology | 2 | 12.0 |
Protein C/physiology | 19 | 73.0 |
Cell Adhesion Molecules/*physiology | 2 | 1.0 |
DNA Damage/drug effects | 2 | 4.0 |
*Fluorescent Dyes | 2 | 6.0 |
Lasers | 4 | 3.0 |
Reproducibility of Results | 13 | 0.0 |
HIV Seropositivity/blood | 2 | 8.0 |
Light | 2 | 0.0 |
Scattering, Radiation | 2 | 1.0 |
Base Sequence | 86 | 0.0 |
*Genes, APC | 51 | 62.0 |
Genes, myc | 3 | 1.0 |
Oligonucleotides, Antisense | 2 | 2.0 |
Promoter Regions (Genetics) | 18 | 0.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 290 | 0.0 |
Tumor Cells, Cultured | 66 | 0.0 |
Carcinoma/*genetics | 2 | 1.0 |
Colorectal Neoplasms/*genetics | 17 | 7.0 |
Cytoskeletal Proteins/genetics | 10 | 16.0 |
*Gene Frequency | 5 | 0.0 |
Genes, APC | 40 | 47.0 |
*Genes, p53 | 11 | 2.0 |
Genes, ras | 5 | 2.0 |
Male | 389 | 0.0 |
*Mutation | 61 | 1.0 |
Risk Factors | 129 | 2.0 |
Smoking/*adverse effects | 2 | 0.0 |
*Trans-Activators | 42 | 6.0 |
Blotting, Western | 26 | 0.0 |
Case-Control Studies | 56 | 1.0 |
Cell Line | 62 | 0.0 |
Middle Aged | 307 | 0.0 |
Protein C/*physiology | 47 | 85.0 |
Reverse Transcriptase Polymerase Chain Reaction | 12 | 0.0 |
Thrombin/biosynthesis | 8 | 20.0 |
Aged | 204 | 0.0 |
Anticoagulants/administration & dosage | 2 | 14.0 |
Biological Markers/blood | 12 | 0.0 |
Blood Coagulation/drug effects | 15 | 13.0 |
Double-Blind Method | 5 | 0.0 |
Heparin/*administration & dosage | 3 | 9.0 |
Activated Protein C Resistance/etiology | 4 | 100.0 |
Factor Va/genetics/metabolism | 2 | 100.0 |
Kinetics | 78 | 0.0 |
Mutagenesis, Site-Directed | 31 | 1.0 |
Protein C/metabolism/pharmacology | 2 | 100.0 |
Protein S/pharmacology | 7 | 87.0 |
Recombinant Proteins/metabolism | 21 | 0.0 |
Thrombosis/etiology | 7 | 11.0 |
*Antigen Presentation | 10 | 6.0 |
Cells, Cultured | 57 | 0.0 |
Immunization | 3 | 0.0 |
Interferon Type II/secretion | 2 | 1.0 |
Viral Matrix Proteins/immunology | 2 | 20.0 |
Alleles | 31 | 0.0 |
Cell Transformation, Neoplastic/genetics | 4 | 1.0 |
Child | 61 | 0.0 |
Child, Preschool | 35 | 0.0 |
Chromosomes, Human, Pair 3/genetics | 3 | 2.0 |
*DNA Methylation | 41 | 6.0 |
DNA, Neoplasm/chemistry/genetics | 2 | 1.0 |
Gene Expression Profiling | 5 | 0.0 |
*Gene Expression Regulation, Neoplastic | 16 | 1.0 |
*Gene Silencing | 2 | 1.0 |
*Genes, Tumor Suppressor | 32 | 3.0 |
Infant | 22 | 0.0 |
Neoplasms/*genetics/pathology | 2 | 5.0 |
Polymerase Chain Reaction | 95 | 0.0 |
Promoter Regions (Genetics)/*genetics | 6 | 0.0 |
*Tumor Suppressor Proteins | 7 | 0.0 |
Cell Separation | 5 | 0.0 |
Genetic Markers | 17 | 0.0 |
HLA-DR Antigens/biosynthesis | 2 | 2.0 |
Immunophenotyping | 11 | 0.0 |
Interleukin-1/biosynthesis | 2 | 1.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Ligands | 7 | 0.0 |
Membrane Glycoproteins/biosynthesis | 2 | 1.0 |
Adenocarcinoma/*genetics/pathology | 12 | 12.0 |
Aged, 80 and over | 82 | 0.0 |
Colorectal Neoplasms/*genetics/pathology | 10 | 11.0 |
DNA, Neoplasm/*genetics | 6 | 2.0 |
Genes, Tumor Suppressor/physiology | 3 | 6.0 |
*Loss of Heterozygosity | 14 | 3.0 |
Microsatellite Repeats/*genetics | 9 | 3.0 |
Neoplasm Staging | 18 | 0.0 |
Taiwan | 2 | 1.0 |
Arginine/chemistry | 2 | 3.0 |
Binding Sites | 50 | 0.0 |
DNA Mutational Analysis | 49 | 1.0 |
Fibrinolytic Agents/pharmacology | 3 | 14.0 |
Models, Molecular | 25 | 0.0 |
Mutation | 105 | 1.0 |
Protein Binding | 68 | 0.0 |
Protein C/*chemistry/metabolism | 3 | 50.0 |
Dose-Response Relationship, Drug | 38 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 31 | 0.0 |
Fetal Blood | 3 | 2.0 |
Infant, Newborn | 19 | 0.0 |
Protein C/*antagonists & inhibitors/pharmacology | 3 | 100.0 |
Prothrombin/*metabolism | 7 | 21.0 |
Thrombin/*metabolism | 12 | 15.0 |
alpha-Macroglobulins/*pharmacology | 2 | 40.0 |
Adenoma/*genetics | 5 | 6.0 |
DNA Primers | 22 | 0.0 |
Homozygote | 27 | 1.0 |
Immunohistochemistry | 32 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Intestinal Neoplasms/*genetics | 2 | 18.0 |
Karyotyping | 4 | 0.0 |
Loss of Heterozygosity | 29 | 3.0 |
*Blood Coagulation Factors | 14 | 48.0 |
DNA-Binding Proteins/genetics | 6 | 0.0 |
Endothelium, Vascular/cytology/*metabolism | 5 | 2.0 |
Enzyme Activation | 76 | 2.0 |
Gene Expression Regulation | 6 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 7 | 0.0 |
Phosphorylation | 26 | 0.0 |
Protein C/*metabolism | 116 | 76.0 |
Receptor, PAR-1 | 2 | 9.0 |
Receptors, Cell Surface/metabolism | 3 | 0.0 |
Signal Transduction | 18 | 0.0 |
Thrombin/metabolism | 32 | 21.0 |
Transcription Factors/genetics | 4 | 0.0 |
Chromosomes, Human, Pair 5 | 4 | 3.0 |
Colorectal Neoplasms/genetics | 5 | 12.0 |
Cytoskeletal Proteins/*metabolism | 13 | 8.0 |
Down-Regulation | 8 | 0.0 |
Gene Expression Regulation, Neoplastic | 12 | 0.0 |
Germ-Line Mutation | 11 | 2.0 |
Point Mutation | 57 | 2.0 |
*Signal Transduction | 10 | 0.0 |
Trans-Activators/*metabolism | 8 | 0.0 |
Translocation, Genetic | 2 | 0.0 |
Adenomatous Polyposis Coli/*genetics | 25 | 47.0 |
Codon | 4 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics | 4 | 4.0 |
*DNA Mutational Analysis | 5 | 2.0 |
Exons | 19 | 0.0 |
Genes, p53/genetics | 9 | 4.0 |
Genes, ras/genetics | 8 | 7.0 |
Korea | 3 | 1.0 |
Odds Ratio | 13 | 1.0 |
Phosphoric Monoester Hydrolases/*genetics | 3 | 1.0 |
*Polymorphism, Genetic | 8 | 0.0 |
Trans-Activators/genetics | 5 | 2.0 |
Variation (Genetics) | 5 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/genetics | 4 | 16.0 |
DNA/blood | 2 | 1.0 |
Tumor Suppressor Proteins/genetics | 5 | 7.0 |
Carcinoma/*genetics/pathology | 2 | 3.0 |
Cell Differentiation | 10 | 0.0 |
Chronic Disease | 5 | 0.0 |
Gallbladder Neoplasms/*genetics/pathology | 3 | 33.0 |
*Promoter Regions (Genetics) | 7 | 0.0 |
Sulfites/pharmacology | 3 | 9.0 |
Adenomatous Polyposis Coli/*genetics/pathology | 6 | 46.0 |
Adolescent | 102 | 0.0 |
Age Factors | 11 | 0.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Prevalence | 38 | 2.0 |
Trans-Activators/*genetics | 5 | 1.0 |
Adenomatous Polyposis Coli Protein/*genetics | 5 | 55.0 |
COS Cells | 8 | 0.0 |
Cercopithecus aethiops | 4 | 0.0 |
Cloning, Molecular | 14 | 0.0 |
Colorectal Neoplasms | 2 | 7.0 |
*Gene Expression Regulation | 4 | 0.0 |
Molecular Sequence Data | 133 | 0.0 |
Nucleic Acid Conformation | 2 | 0.0 |
Transfection | 25 | 0.0 |
Amino Acid Sequence | 88 | 0.0 |
Calcium/metabolism | 11 | 0.0 |
Chromosome Mapping | 12 | 0.0 |
*Glycoproteins | 4 | 0.0 |
Models, Biological | 16 | 0.0 |
Neoplasms/metabolism | 2 | 2.0 |
Proteins/*genetics | 2 | 0.0 |
Antibodies, Monoclonal | 11 | 0.0 |
Rabbits | 20 | 0.0 |
von Willebrand Factor/*metabolism | 2 | 0.0 |
Activated Protein C Resistance/*blood | 9 | 90.0 |
Autoantibodies/*blood | 3 | 1.0 |
Blood Coagulation Tests | 38 | 19.0 |
Chromatography, Affinity | 6 | 0.0 |
Drug Resistance | 21 | 3.0 |
Factor Va/antagonists & inhibitors | 6 | 85.0 |
Venous Thrombosis/*blood | 3 | 25.0 |
Interferon Type II/biosynthesis | 4 | 0.0 |
Interleukin-2/biosynthesis | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/immunology | 2 | 0.0 |
Amino Acid Substitution | 14 | 1.0 |
Binding Sites/genetics | 4 | 0.0 |
In Vitro | 28 | 0.0 |
Protein C/*chemistry/genetics/*metabolism | 4 | 80.0 |
Protein Structure, Tertiary | 20 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
3T3 Cells | 4 | 0.0 |
Adenomatous Polyposis Coli Protein/*metabolism | 9 | 81.0 |
Cadherins/metabolism | 10 | 8.0 |
Colonic Neoplasms | 2 | 1.0 |
Cytoskeletal Proteins/genetics/*metabolism | 7 | 12.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Genes, Reporter | 4 | 0.0 |
Genetic Vectors | 5 | 0.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
Chromosome Aberrations | 5 | 0.0 |
Genes, APC/*physiology | 4 | 33.0 |
Mutation/genetics | 18 | 1.0 |
Factor Va/*metabolism | 19 | 82.0 |
Fibrin Fibrinogen Degradation Products/analysis | 9 | 6.0 |
Prothrombin/analysis | 4 | 5.0 |
Cell Division | 13 | 0.0 |
Immunoblotting | 11 | 0.0 |
Models, Genetic | 7 | 0.0 |
Precipitin Tests | 15 | 0.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
Biopsy | 3 | 0.0 |
Carcinoma/*genetics/*pathology | 2 | 11.0 |
Cell Transformation, Neoplastic | 3 | 0.0 |
Colorectal Neoplasms/*genetics/*pathology | 6 | 24.0 |
Disease Progression | 13 | 0.0 |
Transcription, Genetic | 7 | 0.0 |
DNA, Neoplasm/analysis | 14 | 1.0 |
Microsatellite Repeats | 30 | 2.0 |
Cytoskeletal Proteins/*biosynthesis/genetics | 2 | 40.0 |
Heterozygote | 56 | 2.0 |
Microsatellite Repeats/genetics | 6 | 1.0 |
Microscopy, Fluorescence | 9 | 0.0 |
Polymorphism, Genetic | 13 | 0.0 |
Trans-Activators/*biosynthesis/genetics | 2 | 7.0 |
Activated Protein C Resistance/*complications | 6 | 100.0 |
*Factor V | 3 | 100.0 |
Magnetic Resonance Imaging | 4 | 0.0 |
Activated Protein C Resistance/genetics | 3 | 75.0 |
Blood Coagulation/physiology | 6 | 10.0 |
European Continental Ancestry Group | 2 | 0.0 |
Phenotype | 46 | 0.0 |
Protein S/physiology | 3 | 75.0 |
Activated Protein C Resistance/*genetics | 11 | 84.0 |
Codon/genetics | 2 | 0.0 |
Glycosylation | 6 | 0.0 |
Mutation, Missense | 2 | 0.0 |
Partial Thromboplastin Time | 78 | 39.0 |
Protein Processing, Post-Translational | 6 | 0.0 |
Prothrombin Time | 18 | 16.0 |
Structure-Activity Relationship | 37 | 1.0 |
Combined Modality Therapy | 7 | 0.0 |
Factor V/analysis | 8 | 53.0 |
Incidence | 16 | 1.0 |
Life Tables | 2 | 1.0 |
Risk | 12 | 1.0 |
Thrombophilia/*etiology | 2 | 50.0 |
Adenocarcinoma/*genetics | 6 | 4.0 |
Clone Cells | 6 | 0.0 |
Esophageal Neoplasms/*genetics | 9 | 12.0 |
Fluorescein Angiography | 2 | 1.0 |
Prospective Studies | 27 | 0.0 |
Colorectal Neoplasms/*genetics/metabolism | 5 | 16.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Exons/genetics | 7 | 0.0 |
Genotype | 32 | 0.0 |
Germ-Line Mutation/*genetics | 3 | 1.0 |
Activated Protein C Resistance | 6 | 54.0 |
Cohort Studies | 15 | 0.0 |
Factor V/*analysis | 2 | 25.0 |
Haplotypes | 5 | 0.0 |
Longitudinal Studies | 3 | 0.0 |
Venous Thrombosis/blood/epidemiology/*etiology | 2 | 66.0 |
*Mutation, Missense | 4 | 0.0 |
Apoptosis | 8 | 0.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Gene Expression Regulation, Developmental | 4 | 0.0 |
Neurons/cytology/metabolism | 2 | 2.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 5 | 1.0 |
Species Specificity | 15 | 0.0 |
Tissue Distribution | 8 | 0.0 |
Trans-Activation (Genetics) | 5 | 0.0 |
Anticoagulants/*immunology | 2 | 40.0 |
Inflammation/immunology | 2 | 1.0 |
Protein C/immunology | 2 | 40.0 |
Rats | 28 | 0.0 |
Cell Nucleus/metabolism/pathology | 2 | 6.0 |
Cytoskeletal Proteins/metabolism | 6 | 2.0 |
DNA Primers/chemistry | 12 | 1.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
*Zebrafish Proteins | 6 | 2.0 |
Antibodies, Monoclonal/chemistry | 2 | 2.0 |
Enzyme Activation/drug effects | 13 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 13 | 0.0 |
Indicators and Reagents | 5 | 1.0 |
Gene Deletion | 14 | 0.0 |
Genes, Tumor Suppressor/*physiology | 8 | 7.0 |
Genes, ras/*genetics | 2 | 2.0 |
Polymerase Chain Reaction/*methods | 4 | 0.0 |
Sensitivity and Specificity | 51 | 1.0 |
Carcinoma, Small Cell/*genetics | 2 | 3.0 |
DNA, Neoplasm/*analysis | 6 | 3.0 |
Gene Expression Regulation, Neoplastic/genetics | 3 | 1.0 |
Lung Neoplasms/*genetics | 3 | 1.0 |
Tumor Markers, Biological/*analysis | 3 | 0.0 |
CpG Islands/*genetics | 7 | 7.0 |
In Situ Hybridization | 3 | 0.0 |
Clinical Trials, Phase II | 2 | 3.0 |
Benzo(a)pyrene/toxicity | 2 | 12.0 |
Cell Differentiation/drug effects | 5 | 0.0 |
Neoplasms/*genetics | 7 | 2.0 |
Pilot Projects | 3 | 0.0 |
Serine Endopeptidases/*metabolism | 2 | 2.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 2 | 1.0 |
English Abstract | 55 | 0.0 |
Metaplasia | 3 | 3.0 |
Polymorphism, Restriction Fragment Length | 13 | 0.0 |
Adenoma/genetics | 4 | 8.0 |
Polymerase Chain Reaction/methods | 8 | 0.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
China/epidemiology | 3 | 1.0 |
Mutation/*genetics | 14 | 1.0 |
Factor V | 5 | 35.0 |
Antibodies, Anticardiolipin/blood | 2 | 7.0 |
Antithrombin III/analysis | 14 | 7.0 |
Lupus Coagulation Inhibitor/blood | 6 | 46.0 |
Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 0.0 |
Protein C Deficiency/blood | 2 | 100.0 |
Protein S Deficiency/blood | 5 | 100.0 |
Prothrombin/genetics | 5 | 8.0 |
Thrombophilia/blood/*complications | 2 | 33.0 |
Protein C/*antagonists & inhibitors/*metabolism | 2 | 100.0 |
Arginine/metabolism | 2 | 3.0 |
Carbohydrate Conformation | 2 | 1.0 |
Catalysis | 7 | 0.0 |
Hydrolysis | 13 | 1.0 |
Protein C/*chemistry | 3 | 33.0 |
Azacitidine/*analogs & derivatives/pharmacology | 3 | 4.0 |
Brain Neoplasms/*genetics | 2 | 1.0 |
*DNA Methylation/drug effects | 2 | 10.0 |
DNA-Binding Proteins/metabolism | 6 | 0.0 |
Epigenesis, Genetic | 2 | 7.0 |
Neoplasm Proteins/*metabolism | 4 | 0.0 |
Nuclear Proteins/metabolism | 5 | 0.0 |
Sex Factors | 5 | 0.0 |
Tumor Suppressor Proteins/metabolism | 2 | 1.0 |
Adenomatous Polyposis Coli/genetics | 8 | 26.0 |
Cadherins/*genetics | 3 | 3.0 |
Cytoskeletal Proteins/*genetics | 10 | 9.0 |
DNA Methylation | 10 | 1.0 |
Neoplasm Recurrence, Local/*genetics | 2 | 12.0 |
Prognosis | 21 | 0.0 |
Gene Expression | 13 | 0.0 |
Mice, Knockout | 7 | 0.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Adenocarcinoma/genetics | 4 | 5.0 |
Adenomatous Polyposis Coli Protein/analysis | 2 | 100.0 |
Cyclin D1/analysis | 2 | 5.0 |
Factor V/*genetics | 103 | 57.0 |
Antibodies, Monoclonal/immunology | 9 | 0.0 |
Area Under Curve | 3 | 0.0 |
Biological Markers | 7 | 0.0 |
C-Reactive Protein/analysis | 4 | 0.0 |
Epitopes/immunology | 2 | 0.0 |
Macromolecular Substances | 13 | 0.0 |
Peptide Fragments/analysis | 4 | 1.0 |
Peptide Hydrolases/analysis | 4 | 3.0 |
Phlebography | 2 | 16.0 |
Protein Conformation | 22 | 0.0 |
ROC Curve | 4 | 2.0 |
Severity of Illness Index | 7 | 0.0 |
Thrombophilia/*blood/genetics | 3 | 75.0 |
Pedigree | 44 | 0.0 |
Recurrence | 17 | 1.0 |
Spain/epidemiology | 4 | 2.0 |
alpha 1-Antitrypsin/analysis | 4 | 4.0 |
Dogs | 8 | 0.0 |
Gastric Mucosa/*pathology | 2 | 8.0 |
Protein p53/analysis | 2 | 0.0 |
Aprotinin/pharmacology | 3 | 14.0 |
Cardiopulmonary Bypass/*adverse effects | 2 | 7.0 |
Factor V/genetics/*physiology | 4 | 100.0 |
Models, Cardiovascular | 2 | 4.0 |
Lupus Erythematosus, Systemic/*complications | 2 | 11.0 |
Family Health | 6 | 0.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
Genetic Screening | 13 | 1.0 |
Breast Neoplasms/*genetics/metabolism | 2 | 1.0 |
CpG Islands | 7 | 2.0 |
Genes, Tumor Suppressor | 15 | 1.0 |
Genetic Predisposition to Disease | 22 | 0.0 |
*Oncogenes | 2 | 0.0 |
Disease-Free Survival | 3 | 0.0 |
Multivariate Analysis | 6 | 0.0 |
Adenomatous Polyposis Coli Protein/genetics | 7 | 43.0 |
Cytoskeletal Proteins/analysis/genetics | 2 | 28.0 |
Proteins/genetics | 5 | 0.0 |
*Repressor Proteins | 9 | 0.0 |
Signal Transduction/*genetics | 3 | 2.0 |
Anticoagulants/*pharmacology | 15 | 16.0 |
Protein C/*pharmacology | 47 | 90.0 |
Protein S/*pharmacology | 3 | 100.0 |
Cell Cycle/physiology | 4 | 1.0 |
Cell Fractionation | 2 | 0.0 |
Fungal Proteins/metabolism | 2 | 1.0 |
Ligases/*metabolism | 6 | 6.0 |
*Saccharomyces cerevisiae Proteins | 10 | 0.0 |
Sequence Alignment | 12 | 0.0 |
Signal Transduction/*physiology | 7 | 0.0 |
Trans-Activators/metabolism | 7 | 0.0 |
Transcription Factors/metabolism | 8 | 0.0 |
*Ubiquitin-Protein Ligase Complexes | 10 | 13.0 |
Ubiquitin-Protein Ligases | 9 | 4.0 |
Xenopus laevis | 2 | 0.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Pigment Epithelium of Eye/*pathology | 2 | 25.0 |
Blood Coagulation | 29 | 17.0 |
Clinical Trials | 3 | 0.0 |
Hela Cells | 17 | 0.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
DNA, Complementary/metabolism | 5 | 0.0 |
Homeodomain Proteins/metabolism | 2 | 2.0 |
Phylogeny | 2 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Sequence Homology, Amino Acid | 16 | 0.0 |
Protein C/drug effects/*metabolism | 2 | 50.0 |
Thromboplastin/pharmacology | 6 | 46.0 |
Age of Onset | 4 | 0.0 |
Antithrombin III/metabolism | 9 | 7.0 |
*Fibrinolysis | 6 | 4.0 |
Follow-Up Studies | 13 | 0.0 |
Protein C/metabolism | 32 | 35.0 |
Protein S/metabolism | 14 | 41.0 |
Cell Nucleus/metabolism | 5 | 0.0 |
DNA-Binding Proteins/physiology | 2 | 0.0 |
Transcription Factors/physiology | 2 | 0.0 |
Chromosome Fragile Sites | 2 | 1.0 |
Gene Rearrangement | 3 | 0.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Peutz-Jeghers Syndrome/*genetics | 2 | 10.0 |
Adenomatous Polyposis Coli/*metabolism | 3 | 42.0 |
Cadherins/chemistry | 2 | 40.0 |
Crystallography, X-Ray | 5 | 0.0 |
Peptides/chemistry | 4 | 1.0 |
Plasmids/metabolism | 5 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 34 | 0.0 |
Drug Combinations | 2 | 0.0 |
Estradiol/adverse effects | 2 | 100.0 |
Factor V/genetics | 32 | 34.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Monocytes/*metabolism | 2 | 0.0 |
Colonic Neoplasms/etiology/*genetics | 3 | 42.0 |
DNA Repair/*genetics | 2 | 0.0 |
Lung Neoplasms/etiology/*genetics | 2 | 7.0 |
Fibrinolysis/physiology | 3 | 6.0 |
Thrombomodulin/*metabolism | 5 | 20.0 |
Activated Protein C Resistance/*diagnosis/genetics | 2 | 100.0 |
Agkistrodon | 2 | 66.0 |
Anticoagulants/therapeutic use | 10 | 14.0 |
Blood Coagulation Tests/*methods | 6 | 37.0 |
Crotalid Venoms | 2 | 50.0 |
Liver Diseases/blood | 2 | 7.0 |
Protein C/pharmacology | 9 | 90.0 |
Thrombosis/genetics | 3 | 33.0 |
Antithrombin III | 3 | 5.0 |
Myocardial Infarction/*blood | 2 | 3.0 |
Peptide Hydrolases/blood | 2 | 4.0 |
Protein C/analysis/*metabolism | 2 | 100.0 |
Protein C Inhibitor/*blood | 2 | 66.0 |
Blood Coagulation Tests/standards | 2 | 66.0 |
Retrospective Studies | 18 | 0.0 |
Thromboembolism/blood | 3 | 37.0 |
Thrombophilia/blood/diagnosis | 2 | 40.0 |
Down-Regulation/drug effects | 3 | 1.0 |
Fibrinolytic Agents/*pharmacology | 3 | 9.0 |
Immunoassay | 2 | 0.0 |
Protein C/metabolism/*pharmacology | 8 | 100.0 |
Umbilical Veins | 7 | 1.0 |
Colectomy | 4 | 14.0 |
Colonoscopy | 3 | 6.0 |
DNA Primers/genetics | 2 | 0.0 |
Feasibility Studies | 2 | 0.0 |
Feces/chemistry | 3 | 6.0 |
Intestinal Mucosa/pathology | 3 | 5.0 |
Mass Screening | 4 | 2.0 |
Risk Assessment | 4 | 0.0 |
Antigen-Presenting Cells/*immunology | 17 | 11.0 |
Cytokines/*physiology | 2 | 1.0 |
Barrett Esophagus/*genetics/pathology | 4 | 33.0 |
Cell Transformation, Neoplastic/*genetics/pathology | 3 | 12.0 |
Esophageal Neoplasms/*genetics/pathology | 3 | 9.0 |
Esophagus/pathology | 4 | 25.0 |
Loss of Heterozygosity/genetics | 4 | 3.0 |
Sequence Analysis, DNA | 11 | 0.0 |
DNA/analysis | 6 | 0.0 |
Activated Protein C Resistance/blood/*complications | 2 | 100.0 |
Protein C/metabolism/physiology | 2 | 100.0 |
Diagnosis, Differential | 7 | 0.0 |
Prothrombin/*genetics | 5 | 7.0 |
Venous Thrombosis/blood/diagnosis/*genetics | 2 | 100.0 |
*Hemostasis | 4 | 3.0 |
Pregnancy/*blood | 6 | 3.0 |
Pregnancy Complications, Hematologic/*blood/diagnosis | 2 | 66.0 |
Cell Nucleus/*metabolism | 4 | 0.0 |
Cytoplasm/metabolism | 5 | 0.0 |
Protein Transport | 3 | 0.0 |
Breast Neoplasms/genetics | 3 | 1.0 |
Cadherins/genetics | 7 | 12.0 |
Colonic Neoplasms/genetics | 6 | 9.0 |
*DNA-Binding Proteins | 4 | 0.0 |
Fungal Proteins/genetics | 2 | 1.0 |
Recombination, Genetic | 3 | 0.0 |
Saccharomyces cerevisiae/*genetics | 2 | 1.0 |
3' Untranslated Regions/genetics | 2 | 2.0 |
Italy/epidemiology | 2 | 0.0 |
*Point Mutation | 49 | 3.0 |
Thrombophilia/*genetics | 7 | 23.0 |
Venous Thrombosis/*epidemiology/genetics | 3 | 100.0 |
Aging/*physiology | 2 | 0.0 |
Sex Characteristics | 4 | 0.0 |
Gene Frequency | 21 | 0.0 |
Italy | 4 | 0.0 |
*Microsatellite Repeats | 3 | 1.0 |
Disease Models, Animal | 15 | 0.0 |
Factor V/antagonists & inhibitors | 2 | 66.0 |
Factor Xa/*antagonists & inhibitors | 2 | 5.0 |
Fibrinolytic Agents/administration & dosage/*pharmacology | 2 | 50.0 |
Haplorhini | 3 | 1.0 |
Membranes, Artificial | 7 | 8.0 |
Thrombosis/*drug therapy | 2 | 28.0 |
Cell Cycle | 7 | 0.0 |
Anticoagulants/*metabolism | 13 | 41.0 |
Arginine/*metabolism | 3 | 6.0 |
Factor Va/genetics/*metabolism | 3 | 75.0 |
Phospholipids/metabolism | 13 | 6.0 |
Protein C/genetics/*metabolism | 6 | 66.0 |
Recombinant Proteins/genetics/metabolism | 6 | 0.0 |
Activated Protein C Resistance/blood/*chemically induced | 2 | 100.0 |
Contraceptives, Oral/*adverse effects | 11 | 50.0 |
Cross-Sectional Studies | 10 | 0.0 |
Thromboembolism/chemically induced | 2 | 28.0 |
Blood Coagulation/*physiology | 18 | 15.0 |
Ceruloplasmin/chemistry | 2 | 40.0 |
Chromosomes, Human, Pair 1/genetics | 3 | 1.0 |
Factor VIII/chemistry | 2 | 50.0 |
Fibrinolysis | 9 | 5.0 |
*Antigens, CD | 2 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Dendritic Cells/immunology | 3 | 2.0 |
Lymphocyte Activation/immunology | 7 | 1.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
T-Lymphocytes/*immunology | 6 | 0.0 |
Calibration | 4 | 2.0 |
Cross Reactions | 2 | 0.0 |
Protein Binding/immunology | 3 | 1.0 |
Protein C/*analysis/immunology/metabolism | 2 | 100.0 |
Reference Standards | 8 | 3.0 |
Administration, Cutaneous | 3 | 3.0 |
Administration, Oral | 10 | 1.0 |
Blood Coagulation Factors/*drug effects | 2 | 40.0 |
Antiphospholipid Syndrome/diagnosis | 2 | 100.0 |
Antithrombins/analysis | 3 | 18.0 |
Factor VIII/analysis | 9 | 8.0 |
Fibrinogen/analysis | 8 | 4.0 |
Protein C/analysis | 13 | 23.0 |
Protein S/analysis | 12 | 35.0 |
Venous Thrombosis/etiology | 5 | 45.0 |
Sepsis/drug therapy | 2 | 40.0 |
Chromosome Deletion | 2 | 0.0 |
Genes, Tumor Suppressor/genetics | 9 | 5.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 3 | 0.0 |
Casein Kinases | 2 | 4.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Glycogen Synthase Kinase 3 | 10 | 10.0 |
Glycogen Synthase Kinases | 5 | 8.0 |
Proteins/*metabolism | 2 | 0.0 |
Adjuvants, Immunologic/*pharmacology | 4 | 2.0 |
Antigen-Presenting Cells/physiology | 2 | 3.0 |
DNA, Bacterial/chemistry | 2 | 25.0 |
*Drosophila Proteins | 5 | 0.0 |
*Lectins, C-Type | 2 | 1.0 |
*Mannose-Binding Lectins | 2 | 4.0 |
Membrane Glycoproteins/physiology | 3 | 1.0 |
Oligodeoxyribonucleotides/pharmacology | 2 | 8.0 |
Receptors, Cell Surface/physiology | 6 | 5.0 |
Receptors, Retinoic Acid/genetics | 3 | 3.0 |
Analysis of Variance | 7 | 0.0 |
Adenomatous Polyposis Coli Protein/*chemistry/genetics/*metabolism | 2 | 100.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Cytoskeletal Proteins/*chemistry/genetics/*metabolism | 2 | 50.0 |
Protein Kinases/genetics/metabolism | 2 | 5.0 |
Proto-Oncogene Proteins/metabolism | 4 | 0.0 |
Blood Pressure/drug effects | 2 | 0.0 |
Blood Coagulation Factors/physiology | 4 | 30.0 |
Endothelium, Vascular/cytology/drug effects/*metabolism | 3 | 3.0 |
Antigens, CD/metabolism | 3 | 0.0 |
*Proto-Oncogene Proteins | 4 | 0.0 |
Up-Regulation | 10 | 0.0 |
Adenomatous Polyposis Coli Protein | 46 | 59.0 |
Evolution | 2 | 0.0 |
Fungal Proteins/physiology | 2 | 8.0 |
Microtubules/*metabolism | 3 | 4.0 |
Centrifugation | 2 | 2.0 |
Chemical Fractionation | 2 | 2.0 |
Chromatography, Gel | 5 | 0.0 |
Liposomes/chemistry/metabolism | 2 | 15.0 |
Phosphatidylcholines/metabolism | 3 | 3.0 |
Phosphatidylserines/metabolism | 3 | 5.0 |
Protein C/metabolism/*physiology | 5 | 100.0 |
DNA, Neoplasm/genetics/metabolism | 2 | 2.0 |
O(6)-Methylguanine-DNA Methyltransferase/genetics | 5 | 17.0 |
Protein p16/genetics | 5 | 5.0 |
Thrombin/physiology | 4 | 11.0 |
Thrombomodulin/physiology | 4 | 36.0 |
Treatment Outcome | 13 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Inflammation | 2 | 0.0 |
Statistics, Nonparametric | 6 | 0.0 |
Thrombin/analysis | 2 | 11.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
von Willebrand Factor/analysis | 3 | 0.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Fluorescent Dyes | 2 | 0.0 |
*Gene Expression Profiling | 3 | 0.0 |
Liver Neoplasms/*genetics | 3 | 2.0 |
Staining and Labeling/methods | 2 | 1.0 |
Anaphase | 4 | 18.0 |
*Carrier Proteins | 2 | 0.0 |
Microtubules/metabolism | 5 | 4.0 |
Mitosis | 6 | 1.0 |
Nocodazole/pharmacology | 6 | 4.0 |
Protein C/*genetics/*metabolism | 4 | 100.0 |
Cell Count | 7 | 0.0 |
HLA-DR Antigens/metabolism | 3 | 2.0 |
Isoantigens/immunology | 4 | 4.0 |
*Ultraviolet Rays | 2 | 0.0 |
*Blood Coagulation Tests | 3 | 13.0 |
Chromogenic Compounds/metabolism | 3 | 37.0 |
Factor V Deficiency/*blood/genetics | 2 | 100.0 |
Factor VIII/*analysis | 2 | 6.0 |
False Negative Reactions | 2 | 1.0 |
Lupus Coagulation Inhibitor/physiology | 3 | 100.0 |
*Reagent Kits, Diagnostic | 6 | 10.0 |
Reference Values | 24 | 0.0 |
Thrombophilia/blood | 2 | 25.0 |
Genes, APC/genetics | 6 | 54.0 |
Genetic Counseling | 3 | 1.0 |
Switzerland | 2 | 2.0 |
Antigens, CD1/metabolism | 2 | 5.0 |
Cytotoxicity, Immunologic | 4 | 0.0 |
K562 Cells | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 3 | 0.0 |
Neutrophils/enzymology | 2 | 2.0 |
Protein C/*analysis | 13 | 22.0 |
Immune Tolerance/drug effects | 2 | 7.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Antigen-Presenting Cells/*physiology | 5 | 14.0 |
*Nuclear Proteins | 4 | 0.0 |
Blood Pressure | 2 | 0.0 |
Hepatic Artery | 3 | 5.0 |
Perfusion | 2 | 0.0 |
Swine | 7 | 0.0 |
Thrombomodulin/*physiology | 2 | 66.0 |
Drug Synergism | 8 | 0.0 |
Factor V/*pharmacology | 3 | 100.0 |
Liver Transplantation/*adverse effects | 2 | 13.0 |
Energy Transfer | 3 | 5.0 |
Fluorescence | 3 | 1.0 |
Molecular Weight | 12 | 0.0 |
Adenoma/*genetics/pathology | 3 | 11.0 |
Biopsy, Needle | 2 | 0.0 |
Culture Techniques | 3 | 0.0 |
Genes, APC/*genetics | 18 | 62.0 |
Genetic Markers/genetics | 3 | 0.0 |
Regression Analysis | 2 | 0.0 |
Cytotoxicity, Immunologic/immunology | 2 | 2.0 |
Epitopes, T-Lymphocyte/immunology | 2 | 2.0 |
Gene Expression Regulation, Viral/immunology | 2 | 15.0 |
*Viral Proteins | 2 | 1.0 |
Heparin, Low-Molecular-Weight/therapeutic use | 2 | 22.0 |
Loss of Heterozygosity/*genetics | 4 | 4.0 |
Predictive Value of Tests | 9 | 0.0 |
Survival Analysis | 10 | 0.0 |
Antigens, CD/biosynthesis/genetics | 2 | 5.0 |
Antigens, CD40/immunology | 2 | 3.0 |
Aorta | 3 | 2.0 |
Signal Transduction/immunology | 3 | 0.0 |
Transplantation, Heterologous | 3 | 0.0 |
Gestational Age | 4 | 0.0 |
1-Carboxyglutamic Acid/*metabolism | 3 | 42.0 |
Phospholipids/*metabolism | 9 | 7.0 |
Recombinant Fusion Proteins/genetics/metabolism | 6 | 0.0 |
Rats, Sprague-Dawley | 5 | 0.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Caspases/metabolism | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Interleukin-8/metabolism | 2 | 1.0 |
Lipopolysaccharides/pharmacology | 8 | 0.0 |
Protein C/*metabolism/pharmacology | 10 | 100.0 |
Factor V/*metabolism | 11 | 78.0 |
Adenoma/genetics/pathology | 5 | 22.0 |
Colorectal Neoplasms/genetics/pathology | 2 | 11.0 |
Cytoskeletal Proteins/chemistry/*genetics | 2 | 25.0 |
Germ-Line Mutation/genetics | 2 | 2.0 |
Polymorphism, Single-Stranded Conformational | 16 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Thrombosis/blood/*etiology/genetics | 3 | 100.0 |
Protein C/chemistry/*metabolism | 7 | 87.0 |
Recombinant Proteins/chemistry/metabolism | 6 | 0.0 |
Gene Silencing | 4 | 1.0 |
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis | 2 | 50.0 |
Genes, p53 | 14 | 3.0 |
Activated Protein C Resistance/*etiology | 2 | 100.0 |
Progesterone/blood | 2 | 0.0 |
Desogestrel/adverse effects | 2 | 66.0 |
Hemostasis/*drug effects | 7 | 10.0 |
Norpregnenes/adverse effects | 2 | 66.0 |
Esophagus/*pathology | 2 | 14.0 |
Mucous Membrane/pathology | 2 | 5.0 |
Carcinoma/genetics | 2 | 6.0 |
Inflammatory Bowel Diseases/*genetics | 2 | 8.0 |
Activated Protein C Resistance/blood/diagnosis/*genetics | 3 | 100.0 |
*Immune Tolerance | 3 | 1.0 |
Melanoma/immunology | 3 | 8.0 |
Mice, Inbred BALB C | 13 | 0.0 |
T-Lymphocytes/immunology | 9 | 0.0 |
*Cell Cycle Proteins | 4 | 0.0 |
HT29 Cells | 2 | 1.0 |
Kinetochores/metabolism | 2 | 12.0 |
Neoplasm Proteins/*physiology | 2 | 2.0 |
Proteins/genetics/metabolism | 2 | 1.0 |
Intercellular Adhesion Molecule-1/analysis | 2 | 1.0 |
Survival Rate | 6 | 0.0 |
Apoptosis/drug effects | 2 | 0.0 |
Colonic Neoplasms/*genetics/pathology | 6 | 12.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
Cattle | 22 | 0.0 |
Cell Membrane/*metabolism | 3 | 1.0 |
Blood Coagulation Factors/analysis | 5 | 8.0 |
Pre-Eclampsia/genetics | 2 | 28.0 |
Protein C/antagonists & inhibitors/*metabolism | 5 | 55.0 |
Recombinant Proteins/pharmacology | 8 | 0.0 |
Comorbidity | 4 | 1.0 |
Contraceptives, Oral, Hormonal/adverse effects | 3 | 23.0 |
*Down-Regulation | 3 | 0.0 |
Activated Protein C Resistance/*complications/genetics | 3 | 100.0 |
Bleeding Time | 4 | 3.0 |
Feedback | 2 | 1.0 |
Heparin, Low-Molecular-Weight/*therapeutic use | 2 | 10.0 |
Mice, Inbred Strains | 5 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 6 | 2.0 |
Macaca mulatta | 2 | 0.0 |
Genes, p16 | 5 | 5.0 |
Colorectal Neoplasms/metabolism | 2 | 13.0 |
Dinoprostone/metabolism | 2 | 2.0 |
Immunoprecipitation | 2 | 0.0 |
Jurkat Cells | 4 | 0.0 |
Mice, Transgenic | 6 | 0.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 3 | 0.0 |
Ubiquitin/metabolism | 3 | 1.0 |
Blotting, Southern | 6 | 0.0 |
Genes, APC/physiology | 2 | 33.0 |
Surface Plasmon Resonance | 4 | 2.0 |
Anticoagulants/pharmacology | 13 | 18.0 |
Factor V/drug effects | 2 | 100.0 |
Oligopeptides/metabolism | 2 | 3.0 |
Pyrrolidonecarboxylic Acid/analogs & derivatives | 4 | 16.0 |
Thrombin/pharmacology | 14 | 6.0 |
Venous Thrombosis/epidemiology/etiology | 2 | 50.0 |
Activated Protein C Resistance/complications | 2 | 66.0 |
Cross-Over Studies | 3 | 0.0 |
Netherlands | 2 | 1.0 |
Practice Guidelines | 2 | 2.0 |
Cytoskeletal Proteins/chemistry/*metabolism | 2 | 15.0 |
Microtubule-Associated Proteins/*metabolism | 2 | 1.0 |
Adenocarcinoma/*genetics/*pathology | 2 | 12.0 |
Barrett Esophagus/*genetics/*pathology | 2 | 40.0 |
*Chromosome Aberrations | 5 | 0.0 |
Blood Coagulation Factors/metabolism | 3 | 5.0 |
*Fibrinolytic Agents | 2 | 28.0 |
Circular Dichroism | 2 | 0.0 |
Peptide Fragments/chemistry | 2 | 1.0 |
Protein Structure, Secondary | 5 | 0.0 |
von Willebrand Factor/metabolism | 3 | 1.0 |
Activated Protein C Resistance/blood | 4 | 80.0 |
Factor Xa/pharmacology | 2 | 66.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
Thrombosis/etiology/genetics | 4 | 80.0 |
Carboxypeptidase U | 3 | 42.0 |
Fibrinolysis/*drug effects | 7 | 10.0 |
Linear Models | 2 | 0.0 |
Pregnancy Complications, Hematologic/blood | 2 | 66.0 |
Phospholipids/pharmacology | 8 | 24.0 |
Plasma | 3 | 4.0 |
Thrombomodulin | 2 | 100.0 |
Cell Cycle Proteins/genetics | 3 | 3.0 |
Enzyme Activation/genetics | 2 | 2.0 |
Mutation, Missense/*genetics | 2 | 1.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Immunity, Cellular | 4 | 0.0 |
Mice, Inbred C3H | 4 | 0.0 |
Ultraviolet Rays | 5 | 0.0 |
Endothelium, Vascular/*metabolism | 7 | 2.0 |
Factor Va/metabolism | 24 | 80.0 |
Thromboplastin/*metabolism | 6 | 3.0 |
U937 Cells | 4 | 0.0 |
Antigen-Presenting Cells/immunology/metabolism | 4 | 19.0 |
Coculture Techniques | 3 | 0.0 |
Histocompatibility Antigens Class I/analysis | 2 | 2.0 |
*Eye Proteins | 2 | 1.0 |
Microtubule-Associated Proteins/*genetics/metabolism | 2 | 14.0 |
Multigene Family | 2 | 0.0 |
Cell Differentiation/drug effects/immunology | 3 | 4.0 |
Leukocyte Count | 3 | 0.0 |
Macrophages/immunology | 4 | 1.0 |
Mice, Inbred CBA | 3 | 0.0 |
T-Lymphocyte Subsets/immunology | 4 | 1.0 |
Transplantation, Homologous | 5 | 0.0 |
Factor IXa/metabolism | 3 | 30.0 |
Oligopeptides/immunology | 2 | 11.0 |
DNA Repair/genetics | 2 | 1.0 |
Genes, Tumor Suppressor/*genetics | 10 | 3.0 |
Precancerous Conditions/*genetics | 2 | 7.0 |
Factor Va/*chemistry | 2 | 100.0 |
*Models, Molecular | 2 | 1.0 |
Thrombophilia/epidemiology/*genetics | 2 | 22.0 |
Cell-Free System | 2 | 0.0 |
Substrate Specificity | 21 | 0.0 |
Thrombin/*physiology | 3 | 14.0 |
Thrombomodulin/metabolism | 6 | 20.0 |
Anticoagulants/metabolism | 3 | 17.0 |
Biological Transport | 2 | 0.0 |
Blood Platelets/*metabolism | 4 | 1.0 |
Factor Xa/metabolism | 9 | 16.0 |
Prothrombin/metabolism | 14 | 18.0 |
Protein C Inhibitor | 18 | 94.0 |
Cell Survival | 4 | 0.0 |
Cryopreservation | 3 | 2.0 |
Genetic Engineering | 2 | 2.0 |
Antifibrinolytic Agents/metabolism | 2 | 9.0 |
Fibrin Fibrinogen Degradation Products/metabolism | 3 | 3.0 |
Plasminogen Activator Inhibitor 1/blood | 5 | 4.0 |
Factor Va/*antagonists & inhibitors | 9 | 90.0 |
Protein C/*antagonists & inhibitors/metabolism | 6 | 100.0 |
United States | 6 | 0.0 |
Lymphatic Metastasis | 3 | 0.0 |
Oxidation-Reduction | 4 | 0.0 |
Heparin/pharmacology | 15 | 6.0 |
Liver Function Tests | 2 | 1.0 |
Platelet Count | 6 | 1.0 |
Adenoviridae/genetics | 4 | 0.0 |
Antigens, Neoplasm/*immunology | 2 | 1.0 |
Epitopes | 3 | 0.0 |
Neoplasm Proteins/genetics/*immunology | 2 | 14.0 |
Transformation, Genetic | 2 | 1.0 |
*Bile Ducts, Intrahepatic | 2 | 6.0 |
Japan/epidemiology | 3 | 0.0 |
Colorectal Neoplasms/genetics/metabolism/pathology | 2 | 50.0 |
Antibodies, Antiphospholipid/*blood | 4 | 18.0 |
Conserved Sequence | 2 | 0.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Transcription Factors/chemistry/genetics/*metabolism | 2 | 1.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Bone Marrow Transplantation | 4 | 1.0 |
Cell Movement | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Th1 Cells/immunology | 3 | 1.0 |
Anticoagulants/chemistry/metabolism/pharmacology | 3 | 100.0 |
*Intercellular Signaling Peptides and Proteins | 3 | 0.0 |
Complement 3/analysis | 2 | 0.0 |
Activated Protein C Resistance/blood/*genetics | 2 | 66.0 |
*Blood Coagulation | 22 | 10.0 |
Thrombophilia/genetics/physiopathology | 2 | 100.0 |
CpG Islands/immunology | 2 | 15.0 |
Poly I-C/pharmacology | 2 | 8.0 |
Antibodies, Monoclonal/diagnostic use | 5 | 0.0 |
Down-Regulation/immunology | 2 | 2.0 |
Genetic Heterogeneity | 2 | 0.0 |
Ploidies | 4 | 1.0 |
Activated Protein C Resistance/complications/*diagnosis/genetics | 2 | 100.0 |
Anticoagulants/*therapeutic use | 5 | 11.0 |
Factor V/analysis/genetics | 6 | 66.0 |
Heparin/therapeutic use | 6 | 14.0 |
Warfarin/therapeutic use | 7 | 24.0 |
Thromboembolism/genetics | 5 | 71.0 |
Monocytes/drug effects/*metabolism | 3 | 2.0 |
*Blood Coagulation Tests/methods | 3 | 50.0 |
Heterozygote Detection | 8 | 1.0 |
Fibrin Fibrinogen Degradation Products/*metabolism | 2 | 9.0 |
Thromboplastin/*biosynthesis | 2 | 2.0 |
Mutagenesis | 13 | 1.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Ubiquitins/metabolism | 2 | 1.0 |
Protein C/*chemistry/*metabolism | 2 | 100.0 |
Protein S/*metabolism | 13 | 59.0 |
*Arginine | 4 | 14.0 |
Protein C/chemistry/genetics/*metabolism | 2 | 28.0 |
Factor VIIIa/metabolism | 7 | 46.0 |
Protein S/*genetics/metabolism | 5 | 55.0 |
Precancerous Conditions/*genetics/pathology | 4 | 21.0 |
Stomach Neoplasms/*genetics/pathology | 4 | 8.0 |
Venous Thrombosis/genetics | 2 | 28.0 |
Cell Line, Transformed | 4 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 2 | 1.0 |
*Genes, ras | 7 | 3.0 |
Tumor Markers, Biological | 3 | 0.0 |
Gelatinase A/*metabolism | 2 | 6.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 5 | 4.0 |
Antithrombins/pharmacology | 3 | 25.0 |
Cytokines/metabolism | 5 | 1.0 |
Isoflurophate/pharmacology | 2 | 8.0 |
Peroxidase/metabolism | 2 | 1.0 |
Rats, Wistar | 6 | 0.0 |
Activated Protein C Resistance/*metabolism | 2 | 66.0 |
Activated Protein C Resistance/epidemiology/genetics | 2 | 33.0 |
Cell Adhesion | 4 | 0.0 |
Colonic Neoplasms/metabolism | 3 | 5.0 |
Fluorescent Antibody Technique | 5 | 0.0 |
Mice, Nude | 3 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Neoplasms/*metabolism | 2 | 2.0 |
Drug Resistance/genetics | 17 | 10.0 |
Peptide Hydrolases/metabolism | 5 | 3.0 |
Thrombosis/*etiology | 9 | 18.0 |
Mitosis/*physiology | 5 | 5.0 |
Protein p53/genetics/*metabolism | 2 | 1.0 |
Factor VIII/*metabolism | 3 | 5.0 |
Cell Cycle Proteins/genetics/*metabolism | 2 | 1.0 |
Cyclin B/metabolism | 4 | 4.0 |
Ligases/genetics/*metabolism | 2 | 4.0 |
*Mitosis | 3 | 2.0 |
HLA-DR Antigens/analysis | 2 | 0.0 |
Immunosuppressive Agents/pharmacology | 2 | 1.0 |
Monocytes/immunology/metabolism | 2 | 4.0 |
Muromonab-CD3/pharmacology | 2 | 2.0 |
Tetanus Toxoid/pharmacology | 2 | 8.0 |
Neoplasm Recurrence, Local | 3 | 0.0 |
Lupus Coagulation Inhibitor/*blood | 2 | 15.0 |
Peptide Fragments/blood | 2 | 1.0 |
*Amino Acid Substitution | 2 | 2.0 |
Factor V/analysis/*genetics | 5 | 62.0 |
Haplotypes/*genetics | 2 | 1.0 |
Netherlands/epidemiology | 3 | 2.0 |
Postmenopause/blood | 2 | 6.0 |
Lipopolysaccharides/metabolism | 2 | 1.0 |
Immunity, Natural | 3 | 1.0 |
Sequence Deletion | 12 | 0.0 |
Antigens/metabolism | 2 | 3.0 |
Interleukin-12/biosynthesis | 4 | 4.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Protein C Inhibitor/metabolism | 3 | 100.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 4 | 0.0 |
Base Pair Mismatch | 2 | 1.0 |
*Chromosome Mapping | 5 | 0.0 |
*Ovulation Induction | 2 | 4.0 |
Point Mutation/genetics | 4 | 1.0 |
Blood Coagulation/*drug effects | 12 | 9.0 |
Phosphatidylserines/pharmacology | 2 | 18.0 |
Blotting, Northern | 6 | 0.0 |
Hemostasis/*physiology | 4 | 7.0 |
Lipids/*blood | 3 | 0.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
Drug Administration Schedule | 4 | 0.0 |
Drug Therapy, Combination | 4 | 0.0 |
Protein C/analysis/*physiology | 3 | 100.0 |
Protein C Inhibitor/blood/*metabolism | 2 | 100.0 |
Antigens/blood | 4 | 7.0 |
Plasmin/metabolism | 4 | 4.0 |
Protein C/immunology/*metabolism | 3 | 75.0 |
Protein S/immunology/metabolism | 2 | 66.0 |
Renal Dialysis | 3 | 0.0 |
alpha 1-Antitrypsin/metabolism | 2 | 4.0 |
Schistosomiasis mansoni/*immunology | 2 | 5.0 |
Th2 Cells/immunology | 2 | 1.0 |
Antigen-Presenting Cells/immunology | 8 | 2.0 |
Spectrum Analysis, Mass | 3 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Neoplasm Invasiveness/pathology | 2 | 3.0 |
Neoplasm Metastasis | 6 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
Precancerous Conditions/genetics/pathology | 2 | 11.0 |
Chromosomes/*genetics | 2 | 2.0 |
Recombination, Genetic/*genetics | 2 | 2.0 |
Apoptosis/genetics | 2 | 0.0 |
Dose-Response Relationship, Immunologic | 7 | 1.0 |
Cell Communication | 2 | 0.0 |
Liposomes/metabolism | 2 | 3.0 |
Receptors, Cell Surface/*metabolism | 9 | 1.0 |
Histocompatibility Testing | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Genes, DCC | 6 | 31.0 |
Stomach Neoplasms/*genetics | 3 | 2.0 |
*Exons | 8 | 2.0 |
*Germ-Line Mutation | 3 | 0.0 |
Disease Susceptibility | 13 | 1.0 |
Point Mutation/*genetics | 5 | 1.0 |
Russia/epidemiology | 2 | 8.0 |
Age Distribution | 2 | 0.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
*Schizosaccharomyces pombe Proteins | 3 | 3.0 |
Germany/epidemiology | 3 | 2.0 |
Venous Thrombosis/*epidemiology/etiology/genetics | 2 | 66.0 |
Butyrates/pharmacology | 2 | 5.0 |
Cell Line, Tumor | 10 | 0.0 |
Genes, APC/drug effects | 2 | 100.0 |
Activated Protein C Resistance/diagnosis/*genetics | 3 | 100.0 |
Anaphase/drug effects | 2 | 100.0 |
Cyclins/metabolism | 3 | 0.0 |
Metaphase/drug effects | 2 | 66.0 |
Mitosis/drug effects | 2 | 1.0 |
Antibodies, Anticardiolipin/pharmacology | 2 | 100.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Fibrinolysis/drug effects | 2 | 5.0 |
Glycoproteins/pharmacology | 2 | 5.0 |
Protein C/drug effects | 2 | 100.0 |
Activated Protein C Resistance/*diagnosis | 4 | 100.0 |
Postpartum Period | 2 | 2.0 |
Venous Thrombosis/*etiology | 3 | 42.0 |
Recombinant Proteins/administration & dosage | 2 | 2.0 |
Thrombin/*biosynthesis | 5 | 15.0 |
Genome, Human | 3 | 0.0 |
*Frameshift Mutation | 3 | 1.0 |
DNA/genetics | 6 | 0.0 |
Introns | 4 | 0.0 |
Dermatan Sulfate/chemistry/*pharmacology | 2 | 100.0 |
Thromboplastin/metabolism | 5 | 6.0 |
Glycoproteins/*metabolism | 4 | 2.0 |
Ubiquitins/*metabolism | 2 | 1.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics/pathology | 2 | 28.0 |
Cell Death/genetics | 2 | 5.0 |
Cell Division/genetics | 3 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics | 3 | 6.0 |
Colitis, Ulcerative/genetics | 2 | 11.0 |
*Linkage (Genetics) | 3 | 0.0 |
Antigens, CD/biosynthesis | 2 | 0.0 |
Arthritis, Rheumatoid/*immunology | 2 | 0.0 |
Dendritic Cells/*immunology/metabolism | 3 | 6.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/physiology | 2 | 7.0 |
Interleukin-1/physiology | 2 | 2.0 |
Monocytes/immunology | 4 | 1.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Tumor Necrosis Factor-alpha/physiology | 2 | 1.0 |
Microscopy, Confocal | 3 | 0.0 |
Antigen-Presenting Cells/*metabolism | 4 | 40.0 |
Up-Regulation/immunology | 2 | 1.0 |
Cardiolipins/immunology | 3 | 25.0 |
Phospholipids/*immunology | 4 | 40.0 |
Cytoskeletal Proteins/genetics/metabolism | 2 | 8.0 |
Carcinoma, Hepatocellular/*genetics/virology | 2 | 25.0 |
Liver Neoplasms/*genetics/virology | 2 | 25.0 |
Contraceptives, Oral/adverse effects | 3 | 27.0 |
*Disease Models, Animal | 2 | 0.0 |
Neoplasms, Experimental/genetics | 2 | 15.0 |
Syndrome | 3 | 0.0 |
DNA, Neoplasm | 4 | 3.0 |
Proto-Oncogene Proteins/genetics | 3 | 0.0 |
Receptors, Transforming Growth Factor beta/genetics | 3 | 5.0 |
Activated Protein C Resistance/blood/diagnosis | 2 | 66.0 |
Cytoskeletal Proteins/chemistry/genetics/*metabolism | 3 | 37.0 |
Mitotic Spindle Apparatus/metabolism | 2 | 5.0 |
*Mitosis/drug effects | 2 | 22.0 |
Antigen Presentation/*drug effects | 2 | 33.0 |
HLA-DR Antigens/immunology | 2 | 0.0 |
Histocompatibility Antigens Class II/*immunology | 2 | 1.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Macrophage Activation | 2 | 1.0 |
Macrophages, Alveolar/*immunology | 2 | 4.0 |
CDC2 Protein Kinase/metabolism | 3 | 1.0 |
Cell Cycle Proteins/*metabolism | 5 | 1.0 |
CD4-Positive T-Lymphocytes/immunology/pathology | 2 | 5.0 |
Immunoglobulins/metabolism | 3 | 2.0 |
Cytokines/biosynthesis | 3 | 0.0 |
Heparin/*pharmacology | 5 | 3.0 |
Lysine | 2 | 4.0 |
Arginine/genetics | 6 | 3.0 |
Glutamine/genetics | 2 | 4.0 |
Thrombosis/*blood/genetics | 2 | 50.0 |
Protein C/*immunology | 2 | 50.0 |
Activated Protein C Resistance/*epidemiology/genetics | 2 | 100.0 |
Restriction Mapping | 6 | 0.0 |
Carcinoma/*metabolism/pathology | 2 | 3.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Anticoagulants/*administration & dosage | 3 | 7.0 |
Injections, Intravenous | 2 | 0.0 |
Arteriosclerosis/*blood | 3 | 14.0 |
Cholesterol/blood | 2 | 0.0 |
Macaca fascicularis | 3 | 1.0 |
Fatal Outcome | 4 | 0.0 |
Genes, p53/*genetics | 7 | 2.0 |
Sweden/epidemiology | 6 | 5.0 |
Protein S Deficiency/complications | 5 | 55.0 |
India/epidemiology | 2 | 2.0 |
DNA Repair | 4 | 0.0 |
Neoplasm Proteins/genetics | 7 | 1.0 |
Postmenopause/*blood | 2 | 4.0 |
Adenomatous Polyposis Coli Protein/genetics/*metabolism | 2 | 66.0 |
Nucleic Acid Hybridization | 5 | 0.0 |
Tissue Plasminogen Activator/metabolism | 3 | 8.0 |
Urinary Plasminogen Activator/metabolism | 2 | 4.0 |
*Platelet Activation | 2 | 1.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Lymphocytes/metabolism | 3 | 1.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Thrombosis/*immunology | 2 | 40.0 |
Activated Protein C Resistance/*chemically induced | 2 | 100.0 |
Blood Coagulation Tests/*standards | 2 | 40.0 |
Thrombin Time | 3 | 14.0 |
Colonic Neoplasms/*genetics | 5 | 6.0 |
Intestinal Mucosa/metabolism | 2 | 1.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Costs and Cost Analysis | 2 | 3.0 |
DNA | 6 | 0.0 |
DNA Restriction Enzymes | 2 | 0.0 |
Blood Coagulation/drug effects/physiology | 4 | 33.0 |
Thrombomodulin/*metabolism/physiology | 2 | 100.0 |
Thromboplastin/physiology | 2 | 12.0 |
Cell Membrane/metabolism | 9 | 0.0 |
Endopeptidases/metabolism | 2 | 1.0 |
Growth Substances/metabolism | 2 | 1.0 |
Epithelium/pathology | 3 | 2.0 |
Protein C/*therapeutic use | 5 | 71.0 |
Anticoagulants | 4 | 20.0 |
Hamsters | 8 | 0.0 |
Kidney | 3 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Transfection/methods | 2 | 1.0 |
Factor V/genetics/*metabolism | 4 | 80.0 |
Thrombophlebitis/etiology | 4 | 40.0 |
Protein C Inhibitor/pharmacology | 2 | 66.0 |
Binding, Competitive | 6 | 0.0 |
Solubility | 5 | 0.0 |
Factor V/*analysis/genetics | 8 | 88.0 |
Enzyme Precursors/blood | 2 | 25.0 |
Factor V Deficiency/complications/epidemiology/*genetics | 2 | 100.0 |
Cytoskeletal Proteins/biosynthesis/genetics | 2 | 15.0 |
Papio | 3 | 1.0 |
Cell Cycle Proteins/metabolism | 3 | 0.0 |
G1 Phase | 3 | 0.0 |
S Phase | 2 | 0.0 |
Temperature | 4 | 0.0 |
Factor Va/isolation & purification/*metabolism | 3 | 100.0 |
Spectrometry, Fluorescence | 5 | 1.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 2 | 2.0 |
Monocytes/*immunology | 3 | 0.0 |
Phagocytosis | 3 | 0.0 |
Gastric Mucosa/pathology | 3 | 7.0 |
Pancreatic Neoplasms/genetics | 2 | 5.0 |
Peptide Fragments/genetics/metabolism | 2 | 1.0 |
*Chromosome Deletion | 11 | 1.0 |
Thrombophlebitis/*etiology | 5 | 62.0 |
Antibodies, Anticardiolipin/*pharmacology | 2 | 100.0 |
Glycoproteins/*physiology | 5 | 8.0 |
Methods | 2 | 0.0 |
Protein C/*antagonists & inhibitors | 12 | 92.0 |
Amino Acid Substitution/genetics | 3 | 1.0 |
Arginine/*genetics | 4 | 7.0 |
Glutamine/*genetics | 3 | 17.0 |
India | 2 | 0.0 |
Thrombophlebitis/epidemiology/*etiology | 2 | 100.0 |
Integrin alphaXbeta2 | 5 | 13.0 |
Protein S/antagonists & inhibitors/immunology/*physiology | 2 | 100.0 |
Cell Division/drug effects | 5 | 0.0 |
Hemostasis/drug effects | 5 | 15.0 |
Hemostasis | 3 | 2.0 |
Protein C/*pharmacology/physiology | 4 | 100.0 |
Receptors, Cell Surface/immunology | 2 | 5.0 |
Lupus Coagulation Inhibitor/analysis | 2 | 25.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/immunology | 2 | 7.0 |
Synovial Fluid/*immunology | 2 | 3.0 |
Antibodies, Anticardiolipin/physiology | 2 | 100.0 |
Kaolin | 2 | 50.0 |
Phospholipids | 2 | 18.0 |
Antibodies/pharmacology | 4 | 1.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Membrane Lipids/metabolism | 3 | 6.0 |
*Protein Conformation | 4 | 1.0 |
Thromboembolism/*genetics | 4 | 40.0 |
Neoplasms, Multiple Primary/*genetics | 2 | 5.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Adenomatous Polyposis Coli/complications/*genetics | 2 | 66.0 |
Neoplasms, Second Primary/genetics | 2 | 14.0 |
Phosphatidylethanolamines/pharmacology | 2 | 16.0 |
Xenopus | 5 | 0.0 |
*Xenopus Proteins | 3 | 0.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Antigen Presentation | 5 | 1.0 |
CD8-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
Blood Platelets/*secretion | 2 | 18.0 |
Chimera | 2 | 1.0 |
Endocytosis | 2 | 0.0 |
Leukemia, Myeloid/therapy | 2 | 18.0 |
Liver/metabolism | 3 | 0.0 |
Plasma/*metabolism | 2 | 16.0 |
Thrombosis/*chemically induced | 2 | 50.0 |
Contraceptives, Oral, Combined/*adverse effects | 4 | 40.0 |
Carrier Proteins/metabolism | 4 | 0.0 |
European Continental Ancestry Group/genetics | 4 | 0.0 |
Thrombophilia/genetics | 2 | 40.0 |
Mass Screening/*methods | 3 | 5.0 |
Evaluation Studies | 10 | 1.0 |
Preoperative Care/methods | 2 | 7.0 |
Factor V/chemistry/*genetics | 2 | 100.0 |
Homocysteine/*blood | 2 | 0.0 |
Peptide Fragments/metabolism | 4 | 1.0 |
Pulmonary Embolism/blood | 2 | 28.0 |
Thrombophlebitis/*blood | 4 | 44.0 |
Protein S/*chemistry/genetics/*physiology | 2 | 100.0 |
Sex Hormone-Binding Globulin/*chemistry | 2 | 40.0 |
Acid Anhydride Hydrolases/genetics | 2 | 28.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Isoenzymes/genetics | 3 | 0.0 |
p14ARF Protein/genetics | 3 | 14.0 |
Enzyme Activation/drug effects/immunology | 2 | 6.0 |
Protein C/antagonists & inhibitors/*metabolism/pharmacology | 2 | 66.0 |
Blood Coagulation Tests/methods | 4 | 40.0 |
Factor V/chemistry/*metabolism | 2 | 100.0 |
Factor Xa/*metabolism | 3 | 13.0 |
Cyclins/*metabolism | 3 | 1.0 |
Arginine | 6 | 6.0 |
Genes, Retinoblastoma | 5 | 5.0 |
Warfarin/*administration & dosage | 2 | 22.0 |
Protein C/*genetics/metabolism | 4 | 44.0 |
Enzyme Activation/physiology | 4 | 2.0 |
Thrombophlebitis/genetics | 5 | 100.0 |
Protein C/*genetics | 13 | 28.0 |
Antithrombin III Deficiency | 2 | 14.0 |
Cerebral Angiography | 2 | 7.0 |
*Protein C Deficiency | 9 | 19.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Protein Folding | 2 | 0.0 |
Lung Neoplasms/*genetics/pathology | 3 | 3.0 |
Blood Proteins/analysis | 2 | 1.0 |
Pregnancy Trimesters | 2 | 14.0 |
Protein S/*physiology | 6 | 66.0 |
Dimerization | 3 | 0.0 |
Sequence Homology | 2 | 0.0 |
Factor V/*genetics/metabolism | 7 | 87.0 |
*Drug Resistance | 6 | 12.0 |
Platelet Activation | 2 | 1.0 |
Proteins/metabolism | 2 | 0.0 |
Drug Resistance/physiology | 4 | 16.0 |
Reagent Kits, Diagnostic | 2 | 1.0 |
*Alternative Splicing | 2 | 0.0 |
DNA, Complementary | 4 | 0.0 |
Linkage (Genetics) | 5 | 0.0 |
Nucleic Acid Heteroduplexes | 3 | 6.0 |
Cell Transformation, Neoplastic/*genetics | 4 | 2.0 |
*Chromosomes, Human, Pair 18 | 3 | 2.0 |
Laboratory Techniques and Procedures | 2 | 6.0 |
Retinal Vein Occlusion/*blood | 2 | 100.0 |
Endothelium, Vascular/cytology/*drug effects/metabolism | 2 | 2.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Thrombomodulin/*genetics | 2 | 28.0 |
Blood Coagulation Disorders/*diagnosis | 2 | 25.0 |
Factor V Deficiency/*blood/drug therapy | 2 | 100.0 |
Models, Animal | 2 | 0.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Chimeric Proteins/chemistry/metabolism | 2 | 3.0 |
Liposomes | 6 | 2.0 |
Factor V/metabolism | 7 | 36.0 |
Thrombophlebitis/*genetics | 5 | 31.0 |
Serine Proteinase Inhibitors/blood | 2 | 25.0 |
DNA Mutational Analysis/*methods | 2 | 1.0 |
Magnesium/pharmacology | 2 | 1.0 |
Frameshift Mutation | 6 | 1.0 |
Factor V/*analysis/*genetics | 2 | 100.0 |
Germany | 3 | 0.0 |
Histocompatibility Antigens Class II/*metabolism | 2 | 3.0 |
*Protein Structure, Secondary | 2 | 1.0 |
Antibody Specificity | 3 | 0.0 |
Protein S/*chemistry | 2 | 100.0 |
Recombinant Proteins | 4 | 0.0 |
Drug Resistance/*genetics | 4 | 8.0 |
Factor VIII/*genetics | 3 | 7.0 |
Antigens/analysis | 3 | 2.0 |
Fibrin/metabolism | 3 | 4.0 |
*Heterozygote | 5 | 1.0 |
*Homozygote | 4 | 2.0 |
Chromosomes, Human, Pair 5/*genetics | 3 | 3.0 |
Thrombosis/*genetics | 4 | 21.0 |
Antiphospholipid Syndrome/blood | 2 | 50.0 |
Factor V/physiology | 2 | 66.0 |
Antigens/biosynthesis | 2 | 20.0 |
Antigens, CD80/*biosynthesis | 2 | 5.0 |
Hybridomas | 2 | 1.0 |
Intestines/blood supply | 2 | 100.0 |
Genes, MCC/*genetics | 3 | 75.0 |
Lung Neoplasms/*genetics/metabolism | 2 | 5.0 |
Isomerism | 2 | 0.0 |
Colon/metabolism | 2 | 1.0 |
Sepsis/*immunology | 2 | 40.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Mutagenesis, Insertional | 2 | 0.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
Hispanic Americans/genetics | 2 | 5.0 |
Protein C/antagonists & inhibitors/metabolism | 5 | 83.0 |
DNA Damage | 2 | 0.0 |
Protein p53/*metabolism | 2 | 0.0 |
Endothelium, Vascular/drug effects/*metabolism | 2 | 2.0 |
*Protein C | 4 | 100.0 |
Blood Coagulation Factors/*physiology | 2 | 8.0 |
Consensus Sequence | 3 | 0.0 |
Fanconi Anemia/*genetics | 2 | 4.0 |
Adenomatous Polyposis Coli Protein/metabolism | 3 | 42.0 |
Anticoagulants/chemistry/*pharmacology | 2 | 33.0 |
Factor Xa/antagonists & inhibitors | 2 | 4.0 |
Fibrinolytic Agents/chemistry/*pharmacology | 2 | 100.0 |
Molecular Structure | 2 | 0.0 |
Thrombin/*antagonists & inhibitors | 2 | 16.0 |
Urinary Plasminogen Activator/antagonists & inhibitors | 2 | 33.0 |
Pulmonary Embolism/etiology | 3 | 100.0 |
Cross-Linking Reagents | 2 | 0.0 |
*Peptides | 2 | 3.0 |
Protein C Deficiency | 11 | 32.0 |
Factor Va/*genetics | 2 | 100.0 |
Li-Fraumeni Syndrome/genetics | 2 | 12.0 |
Molecular Biology | 2 | 0.0 |
Monocytes/metabolism | 3 | 0.0 |
Cadherins/biosynthesis | 2 | 7.0 |
Peptide Fragments/pharmacology | 2 | 0.0 |
Recombinant Proteins/biosynthesis/chemistry/metabolism | 2 | 2.0 |
Iodine Radioisotopes | 3 | 0.0 |
DNA, Neoplasm/genetics | 8 | 0.0 |
Tumor Markers, Biological/genetics | 2 | 2.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Calcium/pharmacology | 9 | 4.0 |
Oligopeptides | 4 | 12.0 |
Tumor Suppressor Proteins/*metabolism | 2 | 2.0 |
Ubiquitin-Protein Ligase Complexes/*metabolism | 3 | 33.0 |
Arginine/*chemistry | 6 | 28.0 |
Glutamine/*chemistry | 3 | 60.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Blood Platelets/chemistry | 2 | 6.0 |
Phospholipids/blood | 2 | 1.0 |
Factor X/metabolism | 9 | 16.0 |
*Factor Xa | 3 | 60.0 |
Antigens, Bacterial/*immunology | 2 | 1.0 |
Factor V/genetics/physiology | 2 | 66.0 |
Point Mutation/genetics/physiology | 3 | 21.0 |
Protein C/genetics/*physiology | 3 | 75.0 |
Cell Cycle Proteins/genetics/metabolism | 2 | 2.0 |
DNA Replication | 2 | 0.0 |
Peptides/pharmacology | 2 | 1.0 |
*Apoptosis | 2 | 0.0 |
Blood Platelets/*physiology | 5 | 2.0 |
False Positive Reactions | 3 | 1.0 |
Protein C/*metabolism/*pharmacology | 3 | 100.0 |
Pregnancy Complications, Hematologic | 3 | 42.0 |
Factor VIII/metabolism | 5 | 5.0 |
Pregnancy/*metabolism | 2 | 3.0 |
Drug Interactions | 2 | 0.0 |
1-Carboxyglutamic Acid/*chemistry | 2 | 18.0 |
Epidermal Growth Factor/*chemistry | 2 | 3.0 |
Factor X/chemistry | 2 | 50.0 |
Prothrombin/chemistry | 2 | 66.0 |
Thrombin/chemistry | 3 | 33.0 |
Reperfusion Injury/*metabolism | 2 | 33.0 |
Protein C | 6 | 30.0 |
Gene Dosage | 2 | 0.0 |
Colorectal Neoplasms/genetics/metabolism | 3 | 30.0 |
Epithelium/metabolism | 2 | 0.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Factor V/genetics/metabolism | 4 | 66.0 |
Glycoproteins/metabolism | 3 | 1.0 |
Metaphase | 2 | 1.0 |
*Ubiquitin-Conjugating Enzymes | 2 | 2.0 |
Heparin | 3 | 4.0 |
Major Histocompatibility Complex | 3 | 1.0 |
Thrombosis/blood/*genetics | 2 | 28.0 |
Disseminated Intravascular Coagulation/chemically induced/*drug therapy | 2 | 100.0 |
Urine/chemistry | 2 | 8.0 |
Rectal Neoplasms/genetics | 2 | 22.0 |
Guinea Pigs | 3 | 0.0 |
China | 3 | 0.0 |
*Glutamine | 2 | 16.0 |
Japan | 4 | 0.0 |
Genetics, Population | 2 | 0.0 |
Serine/genetics | 2 | 2.0 |
Antibodies, Anticardiolipin/*blood | 2 | 13.0 |
Thrombosis/epidemiology/*genetics | 4 | 100.0 |
DNA/chemistry | 4 | 1.0 |
Heat | 2 | 0.0 |
Mutagenicity Tests | 2 | 1.0 |
Dendritic Cells/*immunology/metabolism/pathology | 2 | 66.0 |
*Anticoagulants | 2 | 16.0 |
Calcium/*metabolism | 3 | 0.0 |
Oncogenes | 3 | 1.0 |
Autoradiography | 3 | 0.0 |
Protein C/genetics | 2 | 13.0 |
CD4-Positive T-Lymphocytes/*immunology | 6 | 0.0 |
CD8-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
*Cytotoxicity, Immunologic | 2 | 0.0 |
Histocompatibility Antigens/analysis | 2 | 3.0 |
*Lymphocyte Activation | 5 | 0.0 |
Fibrinolysis/*physiology | 2 | 2.0 |
Protease Inhibitors/pharmacology | 2 | 0.0 |
Cell Movement/drug effects | 2 | 0.0 |
Epithelial Cells | 2 | 0.0 |
Thrombosis/*blood | 5 | 17.0 |
Thromboplastin/antagonists & inhibitors | 2 | 28.0 |
*Thrombomodulin | 2 | 100.0 |
Cadherins/*metabolism | 2 | 2.0 |
Peptide Mapping | 2 | 0.0 |
Base Composition | 2 | 0.0 |
MEDLINE | 2 | 16.0 |
Antibodies | 6 | 1.0 |
*Partial Thromboplastin Time | 7 | 38.0 |
Factor V/*genetics/physiology | 3 | 100.0 |
*Gene Deletion | 8 | 0.0 |
Genes, DCC/*genetics | 2 | 16.0 |
Factor VIIIa/*metabolism | 3 | 50.0 |
Factor V Deficiency/*complications/epidemiology | 2 | 100.0 |
Blood Coagulation Tests/*instrumentation | 2 | 28.0 |
Culture Media | 2 | 0.0 |
*Gene Therapy | 2 | 0.0 |
Thrombosis/etiology/*genetics | 2 | 66.0 |
Protein C/pharmacology/*physiology | 2 | 100.0 |
Rheology | 2 | 2.0 |
Statistics | 2 | 0.0 |
Thrombophlebitis/blood/*genetics | 3 | 42.0 |
Base Pair Mismatch/genetics | 2 | 4.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Carcinogens | 3 | 3.0 |
Crosses, Genetic | 2 | 0.0 |
Blood Coagulation Disorders/blood/*complications | 2 | 66.0 |
Prothrombin/*analysis | 2 | 6.0 |
Factor V/*genetics/isolation & purification/metabolism | 2 | 100.0 |
*Liver Transplantation | 3 | 2.0 |
*Enzyme-Linked Immunosorbent Assay | 3 | 3.0 |
Protein C Inhibitor/*chemistry | 2 | 100.0 |
Serine Proteinase Inhibitors/*chemistry | 2 | 40.0 |
alpha 1-Antitrypsin/*chemistry | 2 | 100.0 |
Factor V Deficiency/blood | 2 | 100.0 |
Radioligand Assay | 2 | 0.0 |
Factor Xa/metabolism/pharmacology | 3 | 60.0 |
Immune Tolerance | 2 | 0.0 |
Mesenteric Arteries | 2 | 50.0 |
Serine Proteinase Inhibitors/*pharmacology | 3 | 7.0 |
*Alleles | 5 | 0.0 |
Aphidicolin/pharmacology | 2 | 4.0 |
Ovalbumin/immunology | 3 | 6.0 |
Protein Binding/drug effects | 2 | 0.0 |
Thrombomodulin/genetics/*metabolism | 2 | 66.0 |
Blood Coagulation Factors/*metabolism | 3 | 3.0 |
Antithrombin III/physiology | 2 | 40.0 |
Fibrinogen/metabolism | 3 | 1.0 |
Plasminogen Activator Inhibitor 1/metabolism | 2 | 4.0 |
Phospholipids/immunology | 2 | 33.0 |
Biological Markers/analysis | 2 | 0.0 |
Nucleic Acid Amplification Techniques | 2 | 4.0 |
Chromosomes, Human, Pair 3/*genetics | 2 | 0.0 |
Glutathione Transferase/genetics/metabolism | 2 | 1.0 |
Factor VII/analysis | 2 | 6.0 |
Lipoproteins, HDL Cholesterol/blood | 2 | 0.0 |
Factor V Deficiency/*complications/genetics | 2 | 100.0 |
Dimethylnitrosamine/analogs & derivatives | 2 | 50.0 |
Genes, MCC | 2 | 40.0 |
Family | 2 | 0.0 |
Glycoproteins/*pharmacology | 3 | 3.0 |
Thrombophlebitis/complications | 2 | 66.0 |
Radioimmunoassay | 3 | 0.0 |
Protein S/genetics | 2 | 33.0 |
Blood Preservation | 2 | 2.0 |
Thrombophlebitis/blood | 3 | 75.0 |
Australia | 2 | 1.0 |
Hemostasis/genetics | 2 | 33.0 |
Endothelium, Vascular/*physiology | 3 | 2.0 |
Microspheres | 2 | 1.0 |
Gene Library | 3 | 0.0 |
Recombinant Proteins/biosynthesis/isolation & purification/metabolism | 3 | 4.0 |
Protein S Deficiency | 4 | 57.0 |
*Gene Expression | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
*DNA Replication | 2 | 0.0 |
Protein p53/metabolism | 3 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
Macrophages/*metabolism | 2 | 0.0 |
*Complement Inactivators | 3 | 3.0 |
*Variation (Genetics) | 2 | 0.0 |
Antigens, CD14 | 2 | 0.0 |
RNA Interference | 2 | 0.0 |
Blood Platelets/metabolism | 2 | 1.0 |
Platelet Factor 4/*pharmacology | 2 | 7.0 |
Thromboplastin/*antagonists & inhibitors | 2 | 9.0 |
alpha 1-Antitrypsin/pharmacology | 2 | 15.0 |
Automation | 3 | 4.0 |
Heparin/*therapeutic use | 3 | 13.0 |
Protein C/adverse effects/*therapeutic use | 2 | 100.0 |
Protein C/*drug effects | 2 | 100.0 |
Carcinoma, Squamous Cell/*genetics | 4 | 2.0 |
Thrombin/antagonists & inhibitors | 3 | 12.0 |
Fibrin/*metabolism | 2 | 5.0 |
Streptokinase/pharmacology | 2 | 25.0 |
Tissue Plasminogen Activator/pharmacology | 2 | 18.0 |
Calcium/physiology | 2 | 0.0 |
Lupus Coagulation Inhibitor/*analysis | 2 | 33.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
*Chromosomes, Human, Pair 17 | 2 | 0.0 |
*Chromosomes, Human, Pair 5 | 3 | 1.0 |
Prostatic Neoplasms/*genetics | 2 | 1.0 |
Spleen/immunology | 2 | 1.0 |
T-Lymphocytes, Cytotoxic/*immunology | 2 | 0.0 |
Antiplasmin/metabolism | 2 | 7.0 |
Protein C/metabolism/pharmacology/*physiology | 2 | 100.0 |
*Proto-Oncogenes | 2 | 0.0 |
Sequence Analysis | 2 | 0.0 |
Receptors, Thrombin | 4 | 8.0 |
Genital Neoplasms, Female/blood | 2 | 100.0 |
Heparin/metabolism | 3 | 2.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
Chromogenic Compounds | 2 | 9.0 |
Immunosorbent Techniques | 2 | 0.0 |
Antigens, Viral/immunology | 2 | 1.0 |
Immunologic Memory | 4 | 1.0 |
Salmonella/immunology | 2 | 16.0 |
Citric Acid | 2 | 5.0 |
Precipitation | 2 | 1.0 |
Colon/pathology | 2 | 4.0 |
Blood Platelets/drug effects/metabolism | 2 | 4.0 |
Factor VIII/isolation & purification/*metabolism | 2 | 33.0 |
Platelet Aggregation | 2 | 1.0 |
Protease Inhibitors/*blood | 2 | 14.0 |
Protein Kinase C/metabolism | 2 | 0.0 |
Neoplasms, Germ Cell and Embryonal/*genetics | 2 | 16.0 |
DNA, Neoplasm/metabolism | 2 | 1.0 |
Mice, Inbred ICR | 2 | 0.0 |
Pancreatic Neoplasms/*genetics | 2 | 2.0 |
Protein S | 19 | 36.0 |
Occult Blood | 2 | 33.0 |
Silver Staining | 2 | 2.0 |
Factor Va | 4 | 80.0 |
Plasminogen Activator Inhibitor 1/*metabolism | 2 | 9.0 |
Plasminogen Inactivators/*metabolism | 2 | 11.0 |
Saliva/chemistry | 2 | 4.0 |
Blood Proteins/*metabolism | 5 | 2.0 |
Half-Life | 3 | 0.0 |
alpha-Macroglobulins/*physiology | 2 | 66.0 |
DNA/metabolism | 2 | 0.0 |
*Mitotic Spindle Apparatus | 2 | 28.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Lupus Coagulation Inhibitor | 3 | 25.0 |
Lupus Erythematosus, Systemic/blood/immunology | 2 | 25.0 |
Antibody Formation | 3 | 0.0 |
H-2 Antigens/immunology | 2 | 9.0 |
Histocompatibility Antigens Class II/metabolism | 2 | 2.0 |
T-Lymphocytes, Helper-Inducer/immunology | 2 | 1.0 |
Blood Coagulation Factors/analysis/immunology | 2 | 100.0 |
Glycoproteins/*antagonists & inhibitors | 2 | 40.0 |
Immunoglobulin G/physiology | 2 | 10.0 |
Cross Reactions/immunology | 2 | 4.0 |
Rats, Inbred Strains | 2 | 0.0 |
Blood Proteins/*isolation & purification | 2 | 12.0 |
Blood Coagulation Factors/antagonists & inhibitors | 2 | 100.0 |
Blood Proteins/biosynthesis | 2 | 9.0 |
Multienzyme Complexes/*blood/isolation & purification | 2 | 100.0 |
Metaplasia/genetics | 2 | 25.0 |
Cyclin A/metabolism | 2 | 2.0 |
S Phase/*physiology | 2 | 4.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Tumor Markers, Biological/*genetics | 2 | 1.0 |
Factor Xa | 6 | 31.0 |
Hirudins/pharmacology | 2 | 10.0 |
Serine Endopeptidases/metabolism | 4 | 3.0 |
Glycogen Synthase Kinase 3/*metabolism | 2 | 13.0 |
Ovarian Neoplasms/*metabolism/pathology | 2 | 3.0 |
Glycine/*analogs & derivatives/pharmacology | 2 | 40.0 |
Piperidines/pharmacology | 2 | 3.0 |
Plasminogen Activators/*antagonists & inhibitors | 2 | 28.0 |
*Plasminogen Inactivators | 3 | 33.0 |
Thrombophilia/*diagnosis | 2 | 66.0 |
Urinary Plasminogen Activator/*antagonists & inhibitors | 2 | 100.0 |
Nuclear Localization Signal | 2 | 2.0 |
*Complement Activation | 3 | 0.0 |
Lipoproteins/*blood | 2 | 0.0 |
HLA-DR Antigens | 3 | 0.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Blood Coagulation Tests/instrumentation/*methods | 2 | 100.0 |
Coumarins/analysis | 2 | 100.0 |
Fluorescent Dyes/analysis | 2 | 20.0 |
Fluorometry/instrumentation/*methods | 2 | 100.0 |
Oligopeptides/analysis | 2 | 28.0 |
Thrombin/analysis/*biosynthesis | 3 | 50.0 |
*Complement Pathway, Alternative | 2 | 1.0 |
Thrombosis/drug therapy | 2 | 28.0 |
beta-Transducin Repeat-Containing Proteins | 2 | 16.0 |
Peptide Fragments/immunology | 2 | 0.0 |
Genomics | 2 | 4.0 |
Cytosol/metabolism | 2 | 0.0 |
Signal Transduction/drug effects | 2 | 0.0 |
Protein Binding/physiology | 3 | 1.0 |
*Acid Anhydride Hydrolases | 2 | 0.0 |
Venous Thrombosis/blood | 2 | 33.0 |
